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Highlights 
 
➢ A multi-gene host biomarker signature is identified for detecting pulmonary tuberculosis 
from patient blood samples  
➢ The signature discriminates TB from HIV and latent-TB and can serve as an adjuvant 
tool in confirming TB diagnosis   
 
 
Research in Context 
 
Host factors that are altered significantly due to tuberculosis are investigated, with an aim to 
identify a biomarker panel. A network approach provides a genome-wide view of the molecular 
interactions, analogous to a road network of a city. By comparing networks between healthy and 
TB samples, we identify the set of variations in a systematic fashion, analogous to identifying all 
major variations in the traffic flow in a city between two time points. We then apply a series of 
filters to identify the most discriminating genes among them. The 10-gene signature is seen to be 
characteristic of TB.  
 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
2 
 
Abstract 
Efficient diagnosis of tuberculosis (TB) is met with multiple challenges, calling for a shift of 
focus from pathogen-centric diagnostics towards identification of host-based multi-marker 
signatures. Transcriptomics offers a list of differentially expressed genes, but cannot by itself 
identify the most influential contributors to the disease phenotype. Here, we describe a 
computational pipeline that adopts an unbiased approach to identify a biomarker signature.  Data 
from RNA-sequencing from whole blood samples of TB patients were integrated with a curated 
genome-wide molecular interaction network, from which we obtain a comprehensive perspective 
of variations that occur in the host due to TB. We then implement a sensitive network mining 
method to shortlist gene candidates that are most central to the disease alterations. We then apply 
a series of filters that include applicability to multiple publicly available datasets as well as 
additional validation on independent patient samples, and identify a signature comprising 10 
genes - FCGR1A, HK3, RAB13, RBBP8, IFI44L, TIMM10, BCL6, SMARCD3, CYP4F3 and 
SLPI, that can discriminate between TB and healthy controls as well as distinguish TB from 
latent tuberculosis and HIV in most cases. The signature has the potential to serve as a diagnostic 
marker of TB.  
 
Keywords: tuberculosis, biomarkers, network biology, computational medicine, diagnostics  
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Introduction 
Tuberculosis (TB) now ranks along with HIV as the leading cause of death due to an infectious 
agent worldwide, with approximately 10.4 million people estimated to have acquired TB in 
2015, resulting in 1.4 million deaths [1]. These deaths are largely preventable by early and 
efficient diagnosis of the disease. Unfortunately, diagnosis is often delayed due to insensitive and 
time-consuming methods. Present diagnostic measures rely largely on the detection of Mtb in 
patient samples together with radiological assessments, and they have several shortcomings. 
Sputum cultures are the current standard for detecting Mtb, but while sensitive, they take 3-6 
weeks to provide conclusive results, thereby delaying the initiation of treatment. Host-based 
diagnostic methods provide an alternative for early detection of TB onset and enable the 
monitoring of symptomatic changes. IFN-γ release assays (IGRAs) such as the T-SPOT.TB [2, 
3] or the Quantiferon test [4] measure IFN-γ+ production in response to stimulation with Mtb-
specific antigens ESAT6 and CFP10 [5, 6]. However, IGRAs cannot discriminate between active 
and latent Mtb infection, and are thus inadequate for marking the disease status. In the clinic, 
IGRAs are used more often to detect latent tuberculosis than for diagnosis of active disease [7].  
Existing assays that rely on single-marker readouts, such as that of serum deaminase levels [8], 
also suffer from inadequate sensitivity and/or specificity, calling for more effective host-related 
multi-marker signatures that hold promise for applications in prognostic research and vaccine 
trials as well as in monitoring treatment responses. There is thus a current need for a shift from 
investigations on single markers to high-coverage studies that will reveal signatures consisting of 
multiple integrated markers [9]. Recent years have witnessed an increase in host omics data to 
identify specific gene variations upon infection with Mtb, including genetic polymorphisms 
identified by GWAS and linkage and association studies that ascribe host susceptibility to 
infection [10], genome wide expression variations in patient cohorts as compared to healthy 
controls, as well as variations over the course of treatment in the same patient.  
 
Transcriptomics provides global coverage into host responses, and is widely used in TB 
biomarker research [11, 12]. One drawback of microarray technologies is the lack of absolute 
and detailed evaluation of gene expression. Modern deep sequencing technologies provide 
quantitative and qualitative information on gene expression and genomic composition down to 
the single-nucleotide level [13]. RNA sequencing (RNA-Seq) is fast gaining foothold, and 
provides more accurate measurements of transcript levels and their isoforms with greater 
sensitivity than microarrays, as it overcomes probe-dependency [14]. RNA-seq has been applied 
to study host variations due to mycobacterial infections and has led to rich insights, an example 
being dual RNA-sequencing of host and pathogen in Mtb infected Thp-1 cells that indicated a 
simultaneous induction of M. bovis BCG cholesterol degradation genes and a compensatory up-
regulation in the host de novo cholesterol biosynthesis genes [15]. Recently, a whole blood 
signature that could predict the risk of developing active tuberculosis in patients with latent 
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infection was identified by RNA-seq data [16]. 
  
Although the immunological response against Mtb will be primarily focused in the lung, its 
pathologic status is reflected in the peripheral blood by circulating immune cells [17]. Whole 
blood transcriptomic profiles provide global insights into host immune responses in tuberculosis 
and serve as essential tools in determining underlying molecular players of infection.  
 
 A multi-marker set of gene classifiers determined from blood transcriptomic data with 
sufficient discriminatory prowess would thus support current diagnostic measures to enhance 
early detection of TB in the clinic [18]. Gene expression values highlight differentially expressed 
genes (DEGs), which by themselves are indicative of the variations in disease, but further 
selection is required to identify a small biomarker set that is characteristic of the disease.  Such a 
selection, has been achieved using machine learning methods for a number of diseases including 
tuberculosis [19]. Use of networks, however, provides a different perspective to identify DEGs 
that may be functionally linked to other differentially regulated genes, either directly or 
indirectly through other bridging nodes. A systems approach integrating transcriptomic data and 
genome-wide molecular interaction networks is necessary to provide mechanistic insights into 
the nature of dynamic responses to infection and help identify the most significant contributors to 
the disease phenotype. Biological network analysis involves the construction of a pair-wise 
assembly of molecular interactions among cellular components, that will yield a connected 
network of interactions. The network can be compared to a street-map of a city and provides an 
overview of the interconnected routes or in other words the topological architecture of the 
molecular interactions in a cell. Mapping genome-wide expression profiles into molecular 
networks to construct condition-specific response networks provides an unbiased systematic 
approach to enable the identification of combinations of host components that can serve as 
markers for tuberculosis and aid early diagnosis.  
 
India currently leads the world’s burden of tuberculosis, accounting for about 2.8 million 
cases out of the global incidence of 10 million [1]. Omics studies on the Indian population have 
been few and far between. In this study, with an aim to differentiate pulmonary tuberculosis from 
other conditions, we use a new network based pipeline for biomarker discovery. We obtain 
RNAseq data from an Indian cohort and map them onto interaction networks, from which we 
identify the most influential genes in the host whole blood response network to tuberculosis. We 
then apply a series of filters to finally discover a 10-gene validated signature that can 
discriminate TB samples and healthy controls in multiple cohorts from different geographical 
locations and also discriminate between latent and active tuberculosis. In addition, the signature 
distinguishes between TB and HIV and has a potential to be used for diagnosis in the clinical 
setting.  
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Materials and Methods 
 
Study Participants  
Clinical samples were obtained from participants enrolled at National Institute for Research in 
Tuberculosis (NIRT), Chennai: Active TB (BL), IGRA-ve/Healthy controls (HC), and 
IGRA+ve/latent TB (LTB); St. John’s research Institute, Bengaluru (IGRA-ve/Healthy controls 
and HIV+) and Aragyavaram Medical Centre, Madanapalle (IGRA+ve/latent TB).  Patients 
attending the outpatient clinics of NIRT and community controls were enrolled for this study. 
This was a prospective case control study and we enrolled consecutive patients and controls. The 
diagnosis of pulmonary tuberculosis (TB) was based on smear and culture positivity. Chest X-
rays were used to define cavitary disease as well as unilateral versus bilateral involvement. 
Smear grades were used to determine bacterial burdens and classified as 1
+
, 2
+
 and 3
+
. At the 
time of enrolment, all active TB cases had no record of prior TB disease or anti-tuberculosis 
treatment (ATT). Latent tuberculosis (LTB) diagnosis was based on Tuberculin skin test (TST) 
and Quantiferon TB-Gold in Tube ELISA positivity, absence of chest radiograph abnormalities 
or pulmonary symptoms. A positive TST result was defined as an induration at the site of 
tuberculin inoculation of at least 12 mm in diameter to minimize false positivity due to exposure 
to environmental mycobacteria. NTB individuals were asymptomatic with normal chest X-rays, 
negative TST (indurations < 5 mm in diameter) and Quantiferon ELISA results. All participants 
were BCG vaccinated, HIV negative, non-diabetic and had normal body mass index. All 
participants did not exhibit signs or symptoms of any associated lung or systemic disease. 
Standard anti-TB treatment (ATT) was administered to TB individuals using the directly 
observed treatment, short course (DOTS) strategy. At 6 months following ATT initiation, fresh 
plasma samples were obtained. All TB individuals were culture negative at the end of ATT. All 
individuals were examined as part of a study protocol approved by the ‘Internal Ethics 
Committee’ of NIRT and written informed consent was obtained from all participants (Approval 
number NIRTIEC2010002). Table-1 describes the breakdown of different patient classes.  
Clinical details of all enrolled participants are provided in Additional File 2. Samples for RNA 
sequencing were exclusively from NIRT, Chennai. A total of three samples from the IGRA-ve 
and IGRA+ve categories and 4 from the active TB category were used for RNA sequencing. An 
additional 13 active TB, 10 IGRA-ve, 9 IGRA+ve and 7 HIV+ samples were used for validation 
of gene expression by qRT-PCR. Classification of IGRA-ve and IGRA+ve individuals was done 
on the basis of a QuantiFERON assay.  
 
 
RNA isolation 
Blood (3 ml) from each participant was collected in a Tempus tube, vigorously shaken and 
transported to IISc, Bangalore, where it was stored at -80 ∘C till use. For RNA isolation, frozen 
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TEMPUS tubes were thawed and RNA was extracted using a TEMPUS Spin RNA isolation kit 
(Applied Biosystems) following the manufacturer’s instructions. Briefly, blood from the 
TEMPUS tube was centrifuged at 3000 g for 30 min at 4 ∘C to pellet down the RNA which was 
then re-suspended and loaded onto a spin column for purification. RNA bound to the column was 
eluted and aliquoted RNA was quantified and either subjected to RNA sequencing or converted 
to cDNA for gene expression studies by qRT-PCR.  
 
RNA sequencing RNA isolated from Tempus tubes was quantified and subjected to quality 
control analysis. RNA samples with a RIN >5 were taken further for RNA sequencing. Library 
preparation was performed at Genotypic Technology’s Genomics facility at Bangalore. 5𝜇 g of 
qubit quantified total RNA was taken and enriched for PolyA using NextFlexpolyA Beads. 
Transcriptome library for sequencing was constructed as per the NEXTflexRapid Directional 
RNA-Seqlibrary protocol outlined in “NEXTflex Rapid Directional RNA-Seq Sample 
Preparation Guide” (Cat # 5138-08). Briefly, the PolyA RNA was fragmented for 10 minutes at 
elevated temperature (95C) in the presence of divalent cations and reverse transcribed using first 
strand mix. The RNA-DNA hybrid was cleaned up using Highprep PCR cleanup beads. Second 
strand cDNA was synthesized and end repaired using second strand synthesis mix. Directionality 
is retained by the addition of dUTP at this step. The cDNA was cleaned up using Highprep PCR 
cleanup beads. NEXTflex
TM
 RNA-Seq Barcode Adapters were ligated to the cDNA molecules 
after end repair and addition of “A”- base. SPRI clean-up was performed post ligation. The 
library was amplified using 12 cycles of PCR for enrichment of adapter ligated fragments. The 
prepared library was quantified using qubit and validated for quality by running an aliquot on 
High Sensitivity Bioanalyzer Chip (Agilent).  
 
Read Alignment and Transcript Assembly 
The Tuxedo protocol was followed for the alignment of reads, transcript assembly and analysis. 
The paired–end reads were aligned using TopHat2 (version 2.0.9), using the GRCh38 human 
genome assembly as reference. The discovery of novel junctions was turned off. The transcript 
assembly using the aligned reads was performed using Cufflinks (version v2.2.1). Cuffmerge 
followed by Cuffdiff was used to examine the differential expression of transcripts between the 
different sample groups. The average expression of an individual gene from the Fragment Per 
Kilobase of transcript per Million mapped reads (FPKM) were obtained using Cufflinks. Fold 
changes were computed for genes in Active TB with respect to IGRA-ve healthy controls by 
taking a ratio of their corresponding FPKM values. Differentially expressed genes in TB were 
identified by considering fold change values >2 for upregulated genes and values <0.5 for 
downregulated genes.  
 
cDNA conversion and qRT-PCR  
Approximately 2𝜇 g of RNA from each sample was converted to cDNA using High capacity 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
7 
 
cDNA conversion kit (Applied Biosystems). Selected genes were validated by qPCR using a 
SYBR Green master mix (Applied Biosystems) and specific primers (Table S3) except for SLPI 
which was amplified using a TaqMan master mix and probe. The total reaction volume for 
SYBR green reactions was 25 𝜇 l and for TaqMan it was 10 ul. GAPDH was used as the internal 
housekeeping control gene in both cases. All reactions were carried out in duplicates along with 
a no cDNA negative control using the Step One Plus (Applied Biosystems) instrument. Mean CT 
values were used for calculating relative copy number (RCN) of each gene.  
 
Construction of the human Protein-Protein Interaction Network  
A network of human protein-protein interactions was constructed based on curating high 
confidence, experimentally verified interactions from multiple protein-protein interaction sources 
and pathway databases, as well as from primary literature. This network is termed as hPPiN 
[Sambarey et. al (2016), in Press] [20].  Briefly, the Search Tool for The Retrieval of Interacting 
Genes/Proteins (STRING) version 10 [21] was mined to extract all human interactions with a 
combined score >900, and the functional nature of these interactions was identified from the 
protein actions file. Based on these annotations, the edges were assigned directions, however, 
interactions describing a ‘binding’ event were represented as bidirectional edges. SignaLink v 
2.0 [22] was mined to identify regulatory interactions of transcriptional, post-transcriptional and 
pathway regulators. Additional interactions present in non-diseases conditions were identified 
from the Cancer Cell Map [23], and the BioGRID database [24] was mined to identify unique 
interactions not reported by the other resources used. In addition to PPI databases and resources, 
primary literature was explored to identify experimentally verified interacting proteins in the 
human proteome. Interactions were extracted from Multinet [25], and from the macrophage 
interaction network [26]. From this constructed hPPiN, interactions were extracted for all 
protein-coding genes present in the RNA-Seq dataset.  
 
Condition specific weighted networks  
The FPKM values for all genes were mapped onto the constructed PPI network in the form of 
node and edge weights to generate condition specific response networks. Node and edge weights 
were modified from Sambarey et. al (2013) [26]. The node weight of gene i in condition A is 
given as  
𝑁𝑖(𝐴) = 𝐹𝑃𝐾𝑀𝑖(𝐴)                                                             (1) 
 
The edge weight 𝑊𝑒(𝐴) of edge e comprising genes 𝑖 and 𝑗 in condition 𝐴 is computed as:  
𝑊𝑒𝑖𝑗(𝐴) = 𝐼𝑛𝑣𝑒𝑟𝑠𝑒√𝑁𝑖(𝐴) ∗ 𝑁𝑗(𝐴)                                                (2) 
 
A lower edge weight is indicative of an active edge, wherein the interacting nodes have high 
expression values in that condition.  
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Shortest Path Analysis 
All-vs-all shortest paths were computed for all genes in the network using Dijkstra’s algorithm. 
The algorithm computes minimum weight shortest paths, in which each path begins from a 
source node and ends with a sink node, through interacting proteins, choosing the least-cost edge 
in every step. For a path of length 𝑛 in condition  , the PathCost was computed as a summation 
of the edge weights constituting the path. We have previously performed sensitivity analysis for 
the response network construction, by modifying expression values of genes in a random manner 
to reflect the noise that can be introduced in microarray data. Repeating the pipeline over several 
independent runs incorporating such modifications revealed that the top networks are largely 
robust to minor variations in differential expression [27].  Cytoscape v3.1 [28] was used for 
network analysis and visualization as it is a well-established software used routinely by 
researchers working on biological networks. The implementation of Dijkstra’s algorithm was 
done in Python, a well-established method for computing shortest paths in a network.   
 
Pathway enrichment 
The EnrichR server [29] was used to identify significantly enriched KEGG Pathways and 
WikiPathways, which were pooled and ranked based on the combined score, which is computed 
as c = log(p)*z, where p is the p-value computed using the Fisher exact test, and z is the z-score 
computed by assessing the deviation from the expected rank. 
Results  
An unbiased computational pipeline was developed to integrate RNA-seq data obtained from TB 
patients and corresponding healthy controls into a global protein-protein interaction network, 
resulting in the generation of condition specific networks. The highest activity network unique to 
active TB was identified in which the upregulated genes were shortlisted, and their outward 
reachability was measured to determine the extent to which these DEGs exert their effects in the 
network. The expression profiles of these significant and central genes were then monitored over 
treatment, and those that responded to therapy were further filtered, and among these, those with 
significant upregulation and a q value <0.05 were selected. Additionally, the prediction potential 
of these genes was tested on existing transcriptomic datasets to assess their ability in 
discriminating TB samples from corresponding healthy controls (HC) and other diseases. These 
predicted markers were then subjected to experimental verification by RT-PCR on additional TB 
samples, and were also compared with latent infection and HIV to finally shortlist a list of 10 
genes that can serve as potential markers for diagnosis in tuberculosis. Figure 1 illustrates the 
developed pipeline and the number of genes that were filtered at every step. 
 
Differentially abundant transcripts highlight an active signaling response in tuberculosis 
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Whole blood samples were taken from three healthy controls (HC), three patients with baseline 
tuberculosis (BL) which were subsequently followed up after six (FU1) and twelve (FU2) 
months of treatment. Details about the patient groups, time of sample extraction and number of 
samples are provided in Table 1. The RNA-sequencing was performed as described in the 
Methods. Median FPKM values for the genes across samples were considered as representative 
expression values for each condition. Differentially expressed genes were identified by 
computing fold change values relative to the control for baseline tuberculosis (BL/HC), while 
their dynamic changes over treatment were captured by taking fold changes relative to their 
values in disease (FU1/BL and FU2/BL respectively). The list of fold change values for all genes 
and their q-value is provided in Additional file 1. There were 525 genes up-regulated and 125 
genes down regulated in BL, based on a two-fold difference and a q value <0.05 (Supplementary 
Figure S1). Supplementary Figure S2 depicts the Gene Ontology (GO) processes that are 
enriched by these DEGs.  
 
The processes captured by the identified upregulated genes involve the Type I and Type II 
interferon processes, cytokine signalling mediated by IL-4, IL-6, IL-2, IL-7, TGF-beta, TNF 
pathway, chemokine signalling, TLR pathway, and the Age/Rage pathway, among others. These 
processes broadly capture the innate immune response at play during active infection. To 
determine the genes that contribute most significantly to these biological processes, we adopted a 
networks approach. 
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Table 1. Breakdown of patient classes recruited for this study 
Condition No. of 
Samples 
Age 
range 
(yrs) 
Gender 
Male (M), 
Female (F) 
Clinical Summary 
Active TB 19 18-52 11M, 8F 11 out of 19 cases are sputum smear positive with 
grade 2 to 3. Chest X-ray is abnormal in all, 13 with 
bilateral and 6 with unilateral abnormality, with 1 to 6 
zones, 6 show cavities and 13 show no cavities. Almost 
all patients show normal hematology 
HC 15 30-60 8M, 7F All are sputum smear negative, chest X-rays appear 
normal, no clinical symptoms of TB and no known 
prior history of TB 
LTB 
IGRA +ve 
13 19-34 11M, 2F All are sputum smear negative, chest X-rays appear 
normal, no clinical symptoms of TB and no known 
prior history of TB 
Condition No. of 
Samples 
Age 
range  
(yrs) 
Gender CD4 cells/mm 
 
Viral load 
copies/ml 
Clinical summary 
HIV 7 25-47 4M, 3F 16 – 28%; Mean: 
20.5 % (Not 
investigated in 2) 
3.4x101 to 
8.2x104 
All patients are 
treatment-naive and 
show normal chest 
x-rays with no 
evidence of TB 
 
Response network facilitates the identification of highest activities in the host and 
determination of most influential nodes in disease 
 
The reconstructed human protein-protein interaction network (hPPiN) consisted of 17,063 
proteins (nodes) and 208,760 interactions (edges) among them, of which 168,238 were uni-
directed and 40,522 were bi-directional interactions. The normalized RNA-seq data had 
expression information measured in terms of FPKM values for 14,394 protein-coding genes, and 
the subsequent interaction network for these genes comprised 192,389 interactions. This network 
is highly dense and largely interconnected, and is seen to follow a scale-free distribution 
attributed to most biological networks. The hPPiN was constructed based on experimentally 
validated physical interactions, with directions assigned based on functional annotations. It is 
thus of higher confidence than similar gene co-expression networks derived based on expression 
patterns alone. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
11 
 
 
The computed median FPKM values for conditions HC, BL, FU1 and FU2 were mapped onto 
hPPiN in the form of node and edge weights, and four corresponding condition-specific networks 
were generated. Shortest path computation for these networks comprising 14,342 genes and 
192,389 interactions resulted in the generation of nearly 1.9 billion paths per network, with only 
paths of lengths two and higher considered for further analysis. All paths were sorted and ranked 
based on their cumulative path score, with lower scores implying higher activity. These paths 
represent possible routes of signaling from a source gene to a target gene across the topology of 
the network, and are optimized based on the least costs for each edge traversed to reach a target 
node. The weights for each edge were formulated to include the gene abundance information of 
the two connecting nodes, with a lower edge weight correlating with higher node weights of the 
nodes constituting the edge. The cumulative PathCost, which is a summation of edge weights in 
a path, is thus reflective of the activity of the nodes involved, with the least-scoring paths taking 
routes through highly upregulated nodes. The frequency distribution of the path costs followed a 
long-tail distribution, where the ‘highest activity’ paths comprising maximally upregulated genes 
were localized in the beginning, followed by paths of lower activity, and the frequency tailed off 
asymptotically. The paths at the lower end of the distribution thus have a smaller probability of 
occurrence in the condition studied. The processes and genes characteristic of any condition are 
more likely to be represented in the ‘highest activity’ end of the distribution, hence the paths 
occurring in the top 99
th
 percentile for each condition-specific network were considered for 
further analysis. 
 
The highest activity paths in the BL response network were compared with the corresponding 
highest activity paths computed for the HC network, and those that were common to both top 
networks were eliminated in the process, as they likely represent constitutive activity in the host 
that is responsible for the regular functioning of the system. Among the 364,965 paths present in 
the 99
th
 percentile of the BL network, 97,909 paths were seen to be uniquely active in BL 
relative to the representative HC top network, and the nodes and edges present in these paths 
resulted in a ‘highest-activity network’ (HAN) for active disease, which we refer to as a TB-
specific response network. This response network comprised 3,060 genes, and represented about 
20% of the total network. Gene enrichment analysis of the nodes in this response network 
identified a more focused set of pathways that are enriched with greater significance as compared 
to mere DEG based enrichment, since the network formulation eliminates noise by considering 
only those genes that are involved in active flows. Cytokine signaling, complement signaling 
pathway, MAPK signaling, platelet activation, apoptosis, phagocytosis, TNF and TLR signaling 
as well as the adaptive immune processes such as the T cell receptor signaling pathway are seen 
to be significantly enriched by the HAN nodes. These processes are reflective of an enhanced 
inflammatory immune response, as well as the early onset of adaptive immunity in the host.  
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The most influential nodes form a highly interconnected sub-network 
The HAN, while reflective of the overall host response in tuberculosis, is still a broad 
representation of the processes triggered in the host. Interestingly, this network showed high 
interconnectivity, implying increased cross-talk and concerted action among genes and processes 
constituting the host’s response to infection. An important feature of a good biomarker is its 
abundance, in that it is measurable in the blood in addition to being differentially regulated in 
disease. We thus focused on those genes in the HAN that had a fold change of 2 and higher in 
infection in addition to having a high abundance, both of which are reflected by the computed 
node weights. There were 276 upregulated nodes present in the top network which contribute to 
the paths of highest activity.   
 
In addition to their node weights, their position in the network as well as the nature and 
abundance of their connecting partners will dictate the extent to which each of these 276 nodes 
influence the host response, with some nodes playing a more important role than the others. A 
node centrality measure termed ‘ripple centrality’ was computed for each of these nodes. The 
ripple score determines how the perturbation of a single node impacts its neighbors, and how 
effectively a change at that node can transmit across the network, leading to the identification of 
the most influential nodes, also known as epicenters. The ripple centrality measure was 
computed using the EpiTracer algorithm [27], which measures the Outward Reachability of a 
given node, a property of its connections as well as its condition-specific node weight. Of the 
276 upregulated nodes, 153 nodes had a non-zero ripple score, and a sub-network of these nodes 
and their interacting partners was subsequently analyzed. Figure 2 illustrates the interconnections 
and distribution of these 153 upregulated epicentres (highlighted in red) across the network, and 
the corresponding enrichments of their subnetworks. While the hub nodes which have the highest 
number of partners in the network are highlighted, it is interesting to note that while most of the 
partners of these hubs are not upregulated, collectively these individual subnetworks contribute 
to significantly enriched biological processes, thus emphasizing their importance as downstream 
effectors of the upregulated gene. Most upregulated genes are seen to occupy the central 
positions in the network, as demonstrated in Figure 3. The topological representation of the 
network is a function of the degree or connectivity of the nodes, with nodes of highest 
connectivity placed in the center. Observation of DEGs in the network center implies that the 
infection-induced upregulation is closely connected, with a few molecular players playing a 
more central role in driving the response to disease. 
 
 
The enrichment for the complete network provides deeper insights into the specific processes 
that are upregulated. In addition to the processes the broader inflammatory processes observed in 
Supplementary Figure S2 , specific metabolic processes such as glucose catabolism, fructose 
metabolism, phosphatidylserine, phosphatidylinositol and phosphatidylglycerol metabolism, 
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biosynthesis of glycerolipids and their regulation, NADH regeneration, purine nucleoside 
diphosphate metabolism are seen to be over-represented in this network comprising epicentres 
and their interconnected neighbours of high influence, as described in Figure 3. Fc-gamma 
mediated phagocytosis is seen to be upregulated, in addition to signaling mediated by pattern 
recognition receptors such as Toll Like Receptors and stimulatory c-type Lectin receptor 
pathway. Differential uptake of Mtb by its receptors has been reported to play a role in the 
governing the outcome of infection. Cellular responses to stress are notably activated, including 
regulation of nitric oxide biosynthesis, generation of reactive oxygen species, intrinsic apoptotic 
signaling in response to DNA damage, response to endoplasmic reticulum stress, necrosis, aging 
and senescence. Cytokine signaling mediated by pro-inflammatory cytokines IL2 and IL12 as 
well as the response to interferon gamma, TNF-alpha and Type-I interferons are observed. The 
importance of cytokines in tuberculosis has been well documented, and recent years have placed 
particular emphasis on the Type-I responses, which also show significant enrichment here. The 
adaptive immune responses are strongly characterized with the activation, differentiation, 
aggregation and regulation of T and B lymphocytes, that are all observed in the high activity 
network. 
 
Reversals in gene expression and pathway activity over treatment 
Markers for active infection would ideally get downregulated upon completion of successful 
anti-TB therapy, indicating that their active expression was reflective of the disease state alone. 
Nodes belonging to the sub-network of 153 most influential genes were monitored over the 
corresponding top networks constructed for conditions FU1 and FU2, generated for patients 
monitored at 6 and 12 months of treatment respectively. As determinants of successful anti-
tubercular therapy, genes that are upregulated in active tuberculosis should show a gradual 
decrease in expression values over treatment, eventually reaching levels closer to that of healthy 
controls 12 months post treatment. Markers for active disease alone should therefore rank lower 
in significance in the corresponding treatment top-networks. Of the 153 genes shortlisted in the 
BL top network, 74 genes showed a linear decrease in expression over 6 and 12 months of 
therapy, and were completely absent in the FU2 highest activity network. These 74 genes formed 
a largely interconnected network where they occupy central positions having a high degree, 
thereby enabling them to significantly transmit variations in their expression downstream.  
 
Shortlisting a minimal set of markers for tuberculosis 
Clinical measurements of the 74 genes from patient samples, while feasible, would still pose 
several constraints in developing countries where tuberculosis is most prevalent. Ranking these 
genes to shortlist those which are most significant in terms of abundance, and which can 
discriminate between active tuberculosis patients and healthy controls will lead to the 
identification of a minimal discriminatory signature. We then applied a filter to these 74 genes to 
only select a subset of those genes that were (a) most up-regulated with a significant FDR-
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corrected p-value (qvalue) <0.05 and (b) showed at least a two-fold reversal in expression after 
completion of treatment (FU2). These genes were ranked based on their node weights, which is 
representative of their relative abundance in disease, making them measurable clinically. A total 
of 16 candidate markers were selected, which were RAB13, RBBP8, ADM, CECR6, TNNT1, 
TIMM10, SMARCD3, SLPI, IFI44L, IRF7, BCL6, CYP4F3, HK3, FCGR1A, OSM and MYL9.  
 
The expression of these shortlisted genes was monitored across other reported transcriptomic 
datasets. There exist several publicly available datasets describing whole blood expression 
profiles for pulmonary tuberculosis, largely generated by microarray analysis. Table 2 describes 
the five GEO datasets that were used for comparison in this study. A class prediction step from 
the linear-discriminant analysis (LDA) method was carried out using these 16 genes to determine 
if they could sufficiently separate the TB patient samples from those of healthy controls in all 
five datasets, enabling the assessment of their expression in other measured patient samples 
across different population cohorts. LDA typically includes a training component to select the 
features, followed by a classification component using the identified features. The features in this 
type of a study are the expression values of the individual genes. We have bypassed the selection 
step and instead use the genes selected through the network approach as illustrated in figure 1 
and have used LDA with a 4-fold cross validation to show the predictive potential of these genes 
and their ability to classify TB from HC samples.  In other words, we have used LDA to estimate 
the classification accuracy of the genes that we have already selected through the network-based 
pipeline.  
 
Figure 4 (a) describes the confusion matrices generated by the 16 genes for five datasets, 
depicting the classification of patient samples into healthy controls and tuberculosis patients and 
Figure 4 (b) describes the prediction accuracies for increasing combinations of these 16 genes 
across the datasets described in Table 2. These genes were ranked based on their node weights in 
the RNA-Seq data. Increasing linear combinations of these 16 genes (based on their node 
weights) were used to determine the maximal separability obtained for classification of available 
TB vs HC samples across different microarray datasets.  
 
The 16 genes also form a largely interconnected subnetwork, as depicted in Figure 5 (a). The 
variation of fold changes in their expression over the course of treatment is shown in Figure 5 
(b). 
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Table 2: Whole blood transcriptional profiles used for computational validation 
 
    
Dataset  Number of samples  Population Cohort Reference      
GSE19491 Whole blood 
samples: 54 TB and 
24 HC  
UK, SA  Berry, 2010 [30] 
    
GSE28623 Whole blood from 46 
TB and 37 HC  
The Gambia  Maertzdorf, 2011 
[31]     
GSE34608 Whole blood 
samples:8 TB and 18 
HC  
Germany  Maertzdorf, 2012 
[32] 
    
GSE42834 Whole blood 
samples: 40 TB and 
118 HC 
London  Bloom, 2013 [33] 
    
GSE56153 Whole blood 
samples: 18 TB and 
18 HC  
London  Ottenhoff, 2012 [34] 
 
 
Comparison with published transcriptome-based biomarker studies for tuberculosis 
 
Several studies have focused on identification of biomarkers via whole blood transcriptomics 
utilizing machine learning approaches to determine combinations of markers that can accurately 
distinguish between active TB. Recently, a 3 gene-signature was derived by Khatri and co-
workers [35]. comprising genes DUSP3, GBP5 and KLF2. A study by Maetzdorf et. al (2016) 
[36] also determined a four-gene signature by RT-PCR quantitation in the Indian population 
constituting ID3, GBP1, IFITM3 and P2RY14. These genes were absent in the shortlisted marker 
list predicted by our study. We assessed the presence of these genes signatures in each step of 
our computational pipeline to determine where they were filtered out and why they were absent 
in the final signature predicted in this study. While most of them were reported to be upregulated 
in our generated dataset, they were not all present in the top network, with none of them forming 
epicenters. Further, only 2 of those genes show a variation over treatment in our study, as 
depicted in Table 3.  
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Table 3: Assessment of published signatures in this computational pipeline  
 
        
Filter  Khatri Signature (2016)  Maetzdorf Signature (2016)          
Biomarkers  GBP5 DUSP3 KLF2 ID3 GBP1 IFITM3 P2RY14         
DEG-
RNAseq  
D D ✗  D D D ✗  
        
Top 
Network  
✗  ✓  ✗  ✓  ✓  ✗  ✓  
        
Variation 
Over 
Treatment 
✗  ✗  ✗  ✗  ✓  ✓  ✗  
        
Epicenters  ✗  ✗  ✗  ✗  ✗  ✗  ✗  
 
Experimental Validation by qRT-PCR 
 
We tested 15 (RAB13, RBBP8, ADM, CECR6, TNNT1, TIMM10, SMARCD3, SLPI, IFI44L, 
IRF7, BCL6, CYP4F3, HK3, FCGR1A, OSM) genes from a total of 16 shortlisted candidates 
from the computational pipeline, using qRT-PCR in additional whole blood samples taken from 
patients freshly diagnosed with TB (Table 1). The probe for gene MYL9 did not work, and hence 
it was not considered for validation. In addition, we also tested 6 genes (OASL, MX1, ISG15, 
SOCS3, STAT1, STAT2) belonging to the Type I IFN induced response which was identified to 
be highly up-regulated in active TB as seen in the differentially expressed gene (DEG) list 
derived from RNA Sequencing, as the Type I interferon response has emerged as an important 
host response in tuberculosis. From the list of potentially most significant genes obtained from 
the computational pipeline, expression of RAB13, RBBP8, FCGR1A, IFI44L, TIMM10, BCL6, 
SMARCD3, HK3, CYP4F3 and SLPI was significantly higher in active TB compared to IGRA-
ve/healthy controls as determined by the Mann-Whitney U Test. OASL, MX1 and ISG15 from 
the Type I induced gene list could be validated for high expression in TB compared to IGRA-
ve/healthy controls. Additionally, expression of genes TIMM10, BCL6, SMARCD3 and OASL 
was higher in active TB compared to latent TB and expression of FCGR1A, BCL6, SMARCD3, 
HK3 and SLPI was higher in active TB compared to HIV infection (Fig 6). Using Dunn’s 
multiple comparisons test, BCL6 and SMARCD3 were most significant in distinguishing active 
TB from several other groups: healthy control, latent TB and HIV infection. Interestingly, none 
of the Type I IFN induced genes differentiated between active TB and HIV infection at the N per 
group studied. 
 
The expression values of the 10 genes predicted by the pipeline and subsequently verified by 
qRT-PCR. Expression values for 3 additional genes MX1, OASL and ISG15 were also obtained 
and subjected to patient-wise analysis in the additional samples obtained for verification. Fold 
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changes per gene in TB patient samples were computed with respect to a median HC. As 
observed in Figure 7, in every patient sample, a minimum of 5 genes of the predicted markers 
were seen to be upregulated, with some patients seeing an upregulation in all the genes 
measured. The exception was the sample from patient 28, in whom only 5 genes could be 
measured, of which 2 genes show significant upregulation. Further, every gene showed 
upregulation in all or most of the patients measured, and are ranked by the proportion of samples 
in which they are expressed, with respect to healthy controls. 
 
 
Monitoring expression changes upon treatment 
 
A good biomarker for the disease should show variation over the course of treatment, and the 
pipeline selected those genes that showed a linear decrease in expression after 6 (FU1) and 12 
(FU2) months of treatment. As additional validation, the patients whose blood samples were 
taken at diagnosis for validation by qRT-PCR were followed up for six months and their samples 
were tested to determine if there were any reversals in the upregulation of the shortlisted 
candidate markers. The expression of genes RBBP8, TIMM10, SMARCD3, IFFI44L, BCL6, 
CYP4F3, HK3 and FCGR1A was shown to have a significant reduction after 6 months of 
therapy, while RAB13 did not show much variation. SLPI was not measured in these patients. 
Additionally, three other genes upregulated in TB MX1, OASL and ISG15, which were 
subsequently eliminated at one of the steps of the biomarker identification pipeline, were also 
measured.  Of these, ISG15 showed an increase in expression upon treatment, while MX1 and 
OASL showed significant decrease in expression, indicating changes in the type-1 response upon 
therapy. These results are shown in Figure 8 (a), which indicates that a majority of the genes in 
the panel showed a decrease in expression values upon treatment, with respect to their expression 
levels at diagnosis of TB. Patient-wise variation in gene expression over treatment is shown in 
Figure 8 (b). 
 
 
Specificity of the predicted markers 
 
From the results described above, it is clear that the expression pattern of the 10-gene panel is 
sufficiently characteristic of the TB condition when compared to HC, latent TB and HIV 
samples. Beyond this, a frequent requirement in the clinic is to get a differential diagnosis 
between TB and other diseases whose clinical presentation may resemble pulmonary TB.  
Transcriptome data for other diseases which elicit a similar inflammatory response in the host as 
that of TB were publicly available [30, 33, 37, 38], and we therefore assessed the predictive 
power of the 10 genes to distinguish between TB and other diseases. To determine the specificity 
of our identified signature for these diseases, an LDA was performed on additional samples to 
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determine how many of these samples would be correctly classified into TB and other diseases, 
using only the 10-gene panel by performing the class prediction step of LDA with 4-fold cross 
validation. Table 4 shows the predictive ability of the 10 genes on TB, HIV, LTB and other 
disease samples reported by Kafarou et. al (2013) [37]. Additional File 3 provides details for the 
datasets used and the prediction accuracies obtained using both the 16 gene-set and the 10-gene 
combination to show specificity of TB with respect to other similar diseases. 
 
Table 4. Predictive potential of the 10-gene combination with and without 4-fold cross validation 
on the dataset by Kafarou et. al (2013).  
 
Condition #samples 
C1 
#samples 
C2 
TP TN FP FN Accuracy TP 
noCV 
TN 
noCV 
FP 
noCV 
FN 
noCV 
Accuracy 
noCV 
Malawi             
TB vs HIVLTB 51  
TB 
35 
HIVLTB 
49 31 4 2 0.93 49 31 4 2 0.93 
HIVTB vs 
HIVOD 
50 
HIVTB 
35 
HIVOD 
41 23 12 9 0.75 45 27 8 5 0.85 
TB vs HIVOD 51  
TB 
35 
HIVOD 
46 23 12 5 0.8 48 26 9 3 0.86 
TB vs HIVTB 51 
TB 
50 
HIVTB 
46 37 13 5 0.75 47 41 9 4 0.87 
TB vs LTB 51 TB 36 LTB 42 33 3 9 0.86 43 34 2 8 0.89 
TB vs OD 51 TB 34 OD 47 16 18 4 0.74 49 22 12 2 0.84 
South Africa             
TB vs HIVLTB 47 
TB 
49 
HIVLTB 
38 48 1 9 0.9 38 49 0 9 0.9 
HIVTB vs 
HIVOD 
47 
HIVTB 
57 
HIVOD 
29 48 9 18 0.74 33 52 5 14 0.82 
TB vs HIVOD 47 
TB 
57 
HIVOD 
34 49 8 13 0.8 38 53 4 9 0.88 
TB vs HIVTB 47  
TB 
47 
HIVTB 
37 29 18 10 0.7 36 35 12 11 0.75 
TB vs LTB 47 TB 47 LTB 37 43 4 10 0.85 40 46 1 7 0.91 
TB vs OD 47 TB 49 OD 32 39 10 15 0.74 34 42 7 13 0.79 
 
C1, C2 are Conditions 1 and 2; TP, TN, FP, FN are True Positives, True Negatives, False Positives and False 
Negatives respectively, similar to that in Figure 4.; noCV – no cross validation. Columns 4 to 7 present results with 
a 4-fold cross-validation. 
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Discussion 
 
The host response to Mtb is complex and multifaceted, and involves an elaborate interplay of 
multiple components of the immune system [39]. The transcriptome offers a global dynamic 
view of the changes occurring in the host during infection, and provides a list of differentially 
expressed genes which help characterize specific responses to infection. Whole blood 
transcriptomes are comprehensively covered genomic data that are reflective of condition 
specificity.  While a global view broadly captures the immune response at play during an active 
infection, for ease of diagnostics at the clinical level, further filtering of this list will help 
shortlist the most significant of these genes.  
 
The field of detecting blood biomarkers is rapidly evolving [38, 40, 41]. The key challenge for 
the success of this approach is the robustness of a minimal biomarker to readily distinguish a 
disease state.  This study was designed to identify a minimal biomarker and to validate the 
marker to distinguish extremes of disease. To do so we implemented a networks approach, by 
analyzing these DEGs in the context of their connections and the extent to which they can 
influence their interacting neighbors. Networks provide an overview of the nature of 
connectedness of each participating gene, enabling the identification of hubs, however, by 
themselves they only provide a static picture of the system. Integrating condition specific 
transcriptomic data into the network results in the generated of weighted response networks 
which describe how the changes in expression flow across the interconnected routes in a given 
condition, thereby identifying key regulators of the host response. The hPPiN utilized in this 
study was constructed using only high scoring experimentally validated physical interactions, 
with directions assigned based on functional annotations. It is thus of higher confidence than 
similar gene co-expression networks derived based on expression patterns alone. Each step in the 
pipeline considers a different aspect, which when put together, provide cumulative insights about 
multiple aspects.  While enrichment of the generated response network provides a better 
overview of the underlying processes that are activated during infection, further mining of the 
network is necessary to identify those genes and processes that are primary drivers of the host 
response, which can serve as putative markers for active tuberculosis. 
 
An ideal biomarker should not only be capable of discriminating between disease and healthy 
conditions clearly, but should also be functionally relevant. Analysis of network topology has 
highlighted the central positioning of these predicted markers, which have all shown to exert 
significant influence on their partners and can thus transmit effects of their expression variation 
downstream in the host. Additionally, several of these genes have been implicated in the 
pathobiology of tuberculosis, strengthening their importance as functional biomarkers of disease. 
Infection with Mtb has been reported to alter immuno-metabolism in the host, with the induction 
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of the Warburg effect primarily by HIF-1 recently observed in mice lungs [42]. HK3 has been 
shown to be an important player in the activation of HIF-1 mediated responses, participating in 
stress-mediated energy metabolism and antimicrobial activity. CYP4F3 encodes leukotriene-
B(4) omega-hydrolase 2, and is directly connected to LTA4H in the top response network for 
TB. The expression profile of LTA4H has been shown to influence the TNF-mediated 
inflammatory response by regulating the pro-inflammatory lipid leukotriene B4 in tuberculosis 
as well as in other respiratory diseases such as asthma, and can determine the outcome of 
infection in macrophages [43, 44]. Mtb also promotes its survival in host macrophages by 
dysregulation of lipid mediator balance by enhancing the production of lipoxins, mediated by 
leukotrienes [45]. Genome-wide associated studies (GWAS) of the African population have 
reported RBBP8 to be associated with genetic predisposition to tuberculosis [46]. While its exact 
mechanism of action in tuberculosis is yet unknown, it has been reported to be upregulated in 
several TB transcriptomic studies. The expression of genes RBBP8, RAB13, FCGR1A, 
TIMM10 and SMARCD3 has been demonstrated to significantly distinguish between active TB 
and other diseases such as sarcoidosis and pneumonia (Patents WO2014093872 A1). BCL6 has 
been shown to mediate a sustained Mtb specific CD4 T cell response in addition to regulating 
host apoptotic responses [47]. Both IFI44L and SLPI participate in the interferon-mediated 
inflammation in TB [48], with IFI44L also implicated in lymph-node tuberculosis; SLPI has 
been shown to exhibit antimicrobial activity and also plays an important role in regulating 
apoptosis by interacting with membrane phospholipid scramblase [49]. 
 
Experimental validations in a fresh set of patient samples strengthens our predictions, 
underlining the sensitivity of this methodology which utilized a minimum number of samples to 
derive a signature, but which still should be substantially validated in an additional pool of 
samples from existing datasets in literature with significant prediction accuracies, as well as on 
additional fresh patient cases. The decrease in expression observed for these genes over six 
months of treatment for the patients followed up, further depicts that the candidate genes 
responded to therapy, and that their high expression was representative of a TB-specific 
response. Based on these initial results, it seems likely that the signature will hold true for 
additional patient samples as well. 
 
Difficulties in diagnosis of TB are at times, further compounded by the presence of 
comorbidities such as HIV infection, as well as by a similar inflammatory response observed in 
other diseases such as Sarcoidosis, pneumonia, SLE and Still’s disease. The predicted markers 
are shown to sufficiently distinguish TB from other diseases, by monitoring their differences in 
expression in these diseases, as reported in literature. Further, the discriminatory prowess of the 
signature against HIV was validated experimentally by qRT-PCR.  HIV was chosen for 
comparison as it is well known that a common pathway dysregulated in both HIV and TB is the 
Type 1 interferon pathway [50, 51]. We show in this manuscript by validating the minimal 
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marker in additional samples to those used for sequencing that the marker can distinguish TB 
subjects from healthy controls and HIV infected subjects, with reasonable accuracy.  We wish to 
highlight that the robustness of a marker lies in being successfully validated in samples above 
and beyond those for its initial identification.  We demonstrate that despite the marker being 
identified using RNA-sequencing data from a mere three to four subjects in each group, it was 
validated in several TB samples collected from an additional clinical site, as well as by 
comparing it with expression profiles in other diseases from existing literature. Furthermore, we 
show that the genes in the identified panel respond to treatment and have significantly lower 
levels of expression.  
 
Mapping omics data into genome-scale interaction networks and analysis in terms of the 
pathways and processes associated with these genes have served to provide vital clues about the 
critical differences at a systems level that occur during infection, providing precise suggestions 
for the development of biomarkers that can not only predict disease risk but also monitor 
outcome of therapy. Computational systems level models serve as platforms for rationalizing 
available data both in a molecular bottom-up approach and a top-down approach, so as to derive 
variations in systems properties that may reflect disease sub-types and predict response to a 
particular treatment plan. Such models when supplemented with experimental data can accelerate 
the progress of systems medicine.  
 
The approach implemented in this study is unbiased, in that no other prior knowledge was 
directly used in the selection of genes to include in the signature. Initially all genes and their 
known or predicted interactions are considered to reconstruct the network. The transcriptome 
data has been taken for all genes in a systematic manner. Our pipeline selects genes based on the 
criteria defined at each stage and hence is unbiased or hypothesis-free. Such an approach thus 
offers global insights into the multiple changes occurring in the host upon infection, making it 
feasible to pick among those genes that are topologically significant and functionally relevant, 
and which demonstrate sufficient discriminatory prowess. Signatures and network patterns 
specific to different stages of treatment, have the potential to drive clinical decisions about the 
duration of treatment and specific drug combinations, carving a clear roadmap towards precise 
and personalized medicine. Identification of a marker profile is a step towards aiding early and 
efficient diagnosis of TB, aimed at enabling more effective management of the disease.   
 
Taken together, this is a comprehensive study showing the identification of a robust minimal 
marker gene-set for TB that deserves further validation in larger cohort based studies of both TB 
and other chronic disease states. 
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Figure Legends 
 
Figure 1. The computational pipeline used for biomarker discovery in tuberculosis. The figure 
illustrates the pipeline used in this study, describing multiple filters used to shortlist a minimal 
set of 16 putative biomarkers, which were then subjected to experimental verification by qRT-
PCR, eventually deriving a candidate biosignature of 10 genes in tuberculosis. 
 
Figure 2. The top response network of the most inﬂuential genes (epicentres). Genes that are 
upregulated (FC >2) have been marked in red. The hub nodes are highlighted and the most 
enriched biological processes for their corresponding sub-networks have been illustrated. 
 
Figure 3. Collective enrichment of the highest activity network in TB. The enriched KEGG 
pathways are ranked based on the EnrichR combined score. 
 
Figure 4. (a) Confusion matrices describing predictions for TB and HC samples across 
transcriptomic datasets for 16 genes incorporating a 4-fold cross validation. True Positives (TP) 
indicates TB samples correctly identified as TB, while true negatives (TN) refer to the samples 
that were NOT TB (which means they were HC), that were correctly identified as HC. False 
positives (FP) indicate HC samples identified as TB whereas False negatives (FN) indicate TB 
samples that are identified as HC.   (b) Prediction accuracies obtained for increasing linear 
combinations of 16 genes across 5 whole blood transcriptomic datasets. Datasets GSE34608 and 
GSE28623 did not have the probe for the gene FCGR1A, and the LDA results for these datasets 
exclude that gene.  
 
Figure 5 (a) Interaction network of the 16 shortlisted markers. The 16 genes have been 
highlighted. (b) Reversals in expression over treatment. The fold change values of the 16 
markers show downregulation upon 6 (FU1) and 12 (FU2) months of treatment. Fold changes 
are computed w.r.t a median healthy control. 
 
Figure 6: qRT-PCR verification of the 16 genes shortlisted by the biomarker identification 
pipeline. Comparative analysis of IGRA ve/healthy controls, active pulmonary TB, latent TB and 
HIV infected subjects: All genes listed were veriﬁed by qRT-PCR by the SYBR method, with 
the exception of SLPI, which was veriﬁed by Taqman. GAPDH was used as internal control for 
calculating relative copy number (RCN) of each gene. Statistical signiﬁcance for between group 
RCN diﬀ erences was ﬁrst calculated using Mann-Whitney U test between IGRA-ve and active 
TB subjects. All genes tested were signiﬁcantly diﬀ erent between these two groups using this 
test. P-value shown in each graph was determined by one way ANOVA to correct for multiple 
comparisons; Dunn’s multiple comparisons test was then used to identify signiﬁcant diﬀ erences 
between speciﬁc groups as shown by a line. ∗ = p=0.01; ∗∗p <0.01, ∗∗∗p <0.0001. 
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Figure 7. Patient-wise fold changes in expression of the candidate markers in TB vs HC. Ranked 
list of genes validated by qRT-PCR, with upregulation observed in individual PTB samples with 
respect to a median HC. Genes with a log2FC >1 have been highlighted 
 
Figure 8 (a) qRT-PCR verification of the candidate marker genes after six months of treatment 
(FU1) All genes were veriﬁed by qRT-PCR by the SYBR method. GAPDH was used as internal 
control for calculating relative copy number (RCN) of each gene. Statistical signiﬁcance for 
between group RCN diﬀ erences was calculated using Mann-Whitney U test. p-value shown in 
each graph was determined by one way ANOVA to correct for multiple comparisons (b) Patient-
wise fold changes in expression of the candidate markers in FU1 vs TB. Fold changes were 
computed at FU1 for each gene with respect to their median values in the same patient at 
diagnosis. Genes with a log2FC <-1 are highlighted in blue, and those with a log2FC >1 are 
highlighted in red. Black indicates those genes that were not measured in a given patient sample. 
 
 
Additional Files 
 
Supplementary Figure S1. Identification of differentially expressed genes in Baseline 
Tuberculosis (BL) relative to healthy controls (HC). An absolute log2 fold change of 2 was 
considered as a threshold for differential expression. Both up and downregulated genes with a q 
value (FDR corrected p-value) <0.05 are highlighted in green  
 
Supplementary Figure S2  An overview of biological processes enriched in the set of DEGs. 
The most enriched GO Biological Processes with a p value <0.05 have been represented  
 
Additional File 1. The list of fold change values for all genes and their q-value as determined by 
RNA-sequencing 
 
Additional File 2. Clinical details of enrolled participants in this study 
 
Additional File 3. Prediction accuracies of the shortlisted gene signatures in classifying TB and 
other diseases. 
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Highlights 
 
➢ A multi-gene host biomarker signature is identified for detecting pulmonary tuberculosis 
from patient blood samples  
➢ The signature discriminates TB from HIV and latent-TB and can serve as an adjuvant 
tool in confirming TB diagnosis   
 
Research in Context 
 
Host factors that are altered significantly due to tuberculosis are investigated, with an aim to 
identify a biomarker panel. A network approach provides a genome-wide view of the molecular 
interactions, analogous to a road network of a city. By comparing networks between healthy and 
TB samples, we identify the set of variations in a systematic fashion, analogous to identifying all 
major variations in the traffic flow in a city between two time points. We then apply a series of 
filters to identify the most discriminating genes among them. The 10-gene signature is seen to be 
characteristic of TB.  
